[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355738-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355738-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","enhanced-dynamic-risk-stratification-of-smoldering-multiple-myeloma","Enhanced dynamic risk stratification of smoldering multiple myeloma","","Accurate prediction of progression risk from smoldering multiple myeloma (SMM) to active multiple myeloma (MM) enables individualized early therapy while reducing overtreatment. Current static models do not reflect evolving biomarker trajectories and often require bone marrow biopsies that may be unavailable or inconsistent. Using 2,344 untreated SMM patients from seven international centers, the PANGEA-SMM risk models integrate longitudinal clinical and biological data and identify four evolving biomarkers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/enhanced-dynamic-risk-stratification-of-smoldering-multiple-myeloma/355738/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/enhanced-dynamic-risk-stratification-of-smoldering-multiple-myeloma/355738.png","ImageObject",300,407,{"name":42,"@type":43},"Terk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is risk prediction for SMM progression critical?","Question",{"text":63,"@type":64},"It supports individualized early therapeutic strategies while minimizing the risk of overtreatment and underestimation, since progression timing varies widely across patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What problem do current SMM risk stratification models have?",{"text":68,"@type":64},"They rely on static biomarkers and do not incorporate evolving biomarker trajectories, and they may require bone marrow biopsies that can be unavailable or yield inconsistent results.",{"name":70,"@type":61,"acceptedAnswer":71},"What biomarkers and approach does PANGEA-SMM use?",{"text":72,"@type":64},"PANGEA-SMM models use longitudinal clinical and biological data to incorporate four evolving biomarkers—M-protein, involved/uninvolved serum free light chain ratio, creatinine, and hemoglobin—to better predict time to progression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355738,1790197538,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","nature medicine  \nArticle [https://doi.org/10.1038/s41591-026-04304-x](https://doi.org/10.1038/s41591-026-04304-x)  \nEnhanced dynamic risk stratification of smoldering multiple myeloma  \nReceived: 19 May 2025  \nAccepted: 23 February 2026  \n\n| Published online: 24 March 2026 |\n| --- |\n|  Check for updates |\n\nA list of authors and their affiliations appears atthe end of the paper  \nAccurate prediction of risk of progression from smoldering multiple myeloma (SMM) to active multiple myeloma (MM) is paramount to individualized early therapeutic strategies with minimum risk of overtreatment. Current risk stratification models do not account for evolving biomarker trajectories. We assembled a cohort of 2,344 patients with SMM from seven international centers with longitudinal clinical and biological data to train and validate the Precursor Asymptomatic Neoplasms by Group Effort Analysis (PANGEA)-SMM risk models. Four evolving biomarkers were significantly associated with shorter time to progression:  \nM-protein increase ≥0.2 g dl−1, involved/uninvolved serum free light chain ratio increase ≥20, creatinine increase >25% and hemoglobin decrease ≥1.5 g dl−1. PANGEA-SMM outperforms established models, includingthe 20/2/20 and IMWG models, by more accurately predicting progression (C-statistic = 0.79), even without biomarker history (C-statistic = 0.78) or recent bone marrow biopsy (C-statistic = 0.78). We present PANGEA-SMM to the community asan easy-to-use, open-access tool for risk stratification inSMM. Validation tools are available to compare PANGEA-SMM to established models.  \nSmoldering multiple myeloma (SMM) is a biologically heterogeneous precursor to symptomatic multiple myeloma (MM), characterized by highly varying time to progression1. It is currently defined by the presence of a non-IgM M-protein ≥3 g dl−1 or urinary M-protein ≥500 mg per 24 hours and/or 10–60% clonal bone marrow plasma cells (BMPCs) without evidence of any myeloma-defining events1. Current models to stratify patients by the risk of progression from SMM to MM rely on static biomarkers, without using data on the preceding biomarker trajectory. The commonly used 20/2/20 model includes serum M-protein concentration (>2 g dl−1), involved over uninvolved (involved/uninvolved) serum free light chain (sFLC) ratio (>20) and BMPC infiltration (>20%), which are routinely measured in patients with SMM. The International Myeloma Working Group (IMWG) model additionally includes cytogenetic abnormalities such ast(4;14), t(14;16), del(13/13q) and gain(1q)2,3.  \nThese current risk prediction models are well established and provide simple, reliable clinical scores. However, they have several limitations. Most notably, they fail to account for evolving biomarkers  \nthat reflect dynamic disease progression4–12, and they require bone marrow (BM) biopsies, which are often unavailable during follow-up and may have inconsistent results duetothe patchy nature of plasma cell infiltration13. As a result, some high-risk patients go undetected and develop end-organ damage such as bone lesions, despite close monitoring14,15. Conversely, other patients maybe mistakenly labeled as high risk duetothe failure to account for stable biomarker trajectories that imply stable tumor mass overtime16. Therefore, there isan urgent need for more accurate models that use longitudinal, dynamically evolving biomarkers to identify patients with SMMatthe highest risk of progression toovert MM while minimizing the risk of overtreatment or underestimation of progression17–21. This is especially pressing in light of recent data showing the clinical benefit of early treatment with daratumumabin high-riskSMM.  \nTo address these limitations, we analyzed a large cohort of 2,344 patients with untreated SMM to identify new predictive features from evolving biomarkers (including M-protein, sFLC ratio, creatinine and hemoglobin) and assess their contribution to longitudinal risk  \ne-mail: [ltrippa@ds.dfci.harvard.edu","cbCaialGbapF6j8x","https://ap.wps.com/l/cbCaialGbapF6j8x","pdf",5919542,25,"English","# Abstract\n## Rationale and limitations of existing risk models\n## Cohort design and PANGEA-SMM approach\n## Performance of PANGEA-SMM vs established models\n## Clinical definitions of SMM and static models\n## Need for longitudinal dynamic biomarkers\n## Data sources and study setup","[{\"question\":\"Why is risk prediction for SMM progression critical?\",\"answer\":\"It supports individualized early therapeutic strategies while minimizing the risk of overtreatment and underestimation, since progression timing varies widely across patients.\"},{\"question\":\"What problem do current SMM risk stratification models have?\",\"answer\":\"They rely on static biomarkers and do not incorporate evolving biomarker trajectories, and they may require bone marrow biopsies that can be unavailable or yield inconsistent results.\"},{\"question\":\"What biomarkers and approach does PANGEA-SMM use?\",\"answer\":\"PANGEA-SMM models use longitudinal clinical and biological data to incorporate four evolving biomarkers—M-protein, involved/uninvolved serum free light chain ratio, creatinine, and hemoglobin—to better predict time to progression.\"}]","Enhanced dynamic risk stratification of smoldering multiple myeloma | PDF",1790120694,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2fee32b0f1e57ea2e15138ea48b4f26c.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c74f078d116eab7609808935ef060e1b.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58a96fa9117373813f8a30e5d5d4d0cf.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4cf65ae36a7d4c8230070d40cdffe0c6.webp",980,1301]